These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38044231)

  • 21. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index.
    Legge A; Kirkland S; Rockwood K; Andreou P; Bae SC; Gordon C; Romero-Diaz J; Sanchez-Guerrero J; Wallace DJ; Bernatsky S; Clarke AE; Merrill JT; Ginzler EM; Fortin PR; Gladman DD; Urowitz MB; Bruce IN; Isenberg DA; Rahman A; Alarcón GS; Petri M; Khamashta MA; Dooley MA; Ramsey-Goldman R; Manzi S; Zoma AA; Aranow C; Mackay M; Ruiz-Irastorza G; Lim SS; Inanc M; van Vollenhoven RF; Jonsen A; Nived O; Ramos-Casals M; Kamen DL; Kalunian KC; Jacobsen S; Peschken CA; Askanase A; Hanly JG
    Arthritis Rheumatol; 2020 Apr; 72(4):658-666. PubMed ID: 31631584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of SLE responder index and lupus low disease activity state in real life: A prospective cohort study.
    Ramirez GA; Canti V; Moiola L; Magnoni M; Rovere-Querini P; Coletto LA; Dagna L; Manfredi AA; Bozzolo EP
    Int J Rheum Dis; 2019 Sep; 22(9):1752-1761. PubMed ID: 31379114
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-Term Clinical Outcome in Systemic Lupus Erythematosus Patients Followed for More Than 20 Years: The Milan Systemic Lupus Erythematosus Consortium (SMiLE) Cohort.
    Gerosa M; Beretta L; Ramirez GA; Bozzolo E; Cornalba M; Bellocchi C; Argolini LM; Moroni L; Farina N; Segatto G; Dagna L; Caporali R
    J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
    Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
    Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Early damage as measured by SLICC/ACR damage index is a predictor of hospitalization in systemic lupus erythematosus (SLE).
    Raman L; Yahya F; Ng CM; Sockalingam S; Ramasamy K; Ratnam R; Raja J
    Lupus; 2020 Dec; 29(14):1885-1891. PubMed ID: 33040647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Lofland J; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The majority of Swedish systemic lupus erythematosus patients are still affected by irreversible organ impairment: factors related to damage accrual in two regional cohorts.
    Frodlund M; Reid S; Wetterö J; Dahlström Ö; Sjöwall C; Leonard D
    Lupus; 2019 Sep; 28(10):1261-1272. PubMed ID: 31296137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus.
    Gladman DD; Urowitz MB; Goldsmith CH; Fortin P; Ginzler E; Gordon C; Hanly JG; Isenberg DA; Kalunian K; Nived O; Petri M; Sanchez-Guerrero J; Snaith M; Sturfelt G
    Arthritis Rheum; 1997 May; 40(5):809-13. PubMed ID: 9153540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The SLICC/ACR Damage Index (SDI) may predict adverse obstetric events in patients with systemic lupus erythematosus.
    Lacerda MI; de Jesús GRR; Dos Santos FC; de Jesús NR; Levy RA; Klumb EM
    Lupus; 2021 Oct; 30(12):1966-1972. PubMed ID: 34530654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of disease activity and damage on quality of life in patients with systemic lupus erythematosus: a 2-year prospective study.
    Mok CC; Ho LY; Cheung MY; Yu KL; To CH
    Scand J Rheumatol; 2009; 38(2):121-7. PubMed ID: 18991189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study.
    Golder V; Kandane-Rathnayake R; Hoi AY; Huq M; Louthrenoo W; An Y; Li ZG; Luo SF; Sockalingam S; Lau CS; Mok MY; Lateef A; Franklyn K; Morton S; Navarra ST; Zamora L; Wu YJ; Hamijoyo L; Chan M; O'Neill S; Goldblatt F; Nikpour M; Morand EF;
    Arthritis Res Ther; 2017 Mar; 19(1):62. PubMed ID: 28320433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity.
    Jesus D; Matos A; Henriques C; Zen M; Larosa M; Iaccarino L; Da Silva JAP; Doria A; Inês LS
    Ann Rheum Dis; 2019 Mar; 78(3):365-371. PubMed ID: 30626657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. What is the best instrument to measure disease activity in SLE? - SLE-DAS vs Easy BILAG.
    Inês LS; Fredi M; Jesus D; Shumilova A; Franceschini F; Vital EM
    Autoimmun Rev; 2024 Jan; 23(1):103428. PubMed ID: 37634675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
    Goteti K; French J; Garcia R; Li Y; Casset-Semanaz F; Aydemir A; Townsend R; Mateo CV; Studham M; Guenther O; Kao A; Gastonguay M; Girard P; Benincosa L; Venkatakrishnan K
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):180-195. PubMed ID: 36350330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality.
    Becker-Merok A; Nossent HC
    J Rheumatol; 2006 Aug; 33(8):1570-7. PubMed ID: 16845708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lymphopenia as a risk factor for neurologic involvement and organ damage accrual in patients with systemic lupus erythematosus: A multi-center observational study.
    Yavuz S; Cansu DU; Nikolopoulos D; Crisafulli F; Antunes AM; Adamichou C; Reid S; Stagnaro C; Andreoli L; Tincani A; Moraes-Fontes MF; Mosca M; Leonard D; Jönsen A; Bengtsson A; Svenungsson E; Gunnarsson I; Dahlqvist SR; Sjöwall C; Bertsias G; Fanouriakis A; Rönnblom L
    Semin Arthritis Rheum; 2020 Dec; 50(6):1387-1393. PubMed ID: 32229040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
    Pitsigavdaki S; Nikoloudaki M; Garantziotis P; Silvagni E; Repa A; Marangoni A; Flouri I; Avgoustidis N; Parperis K; Fanouriakis A; Govoni M; Sidiropoulos P; Boumpas DT; Bortoluzzi A; Bertsias G
    Ann Rheum Dis; 2024 Mar; 83(4):464-474. PubMed ID: 38233103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of low disease activity and clinical remission following belimumab treatment in systemic lupus erythematosus.
    Parodis I; Johansson P; Gomez A; Soukka S; Emamikia S; Chatzidionysiou K
    Rheumatology (Oxford); 2019 Dec; 58(12):2170-2176. PubMed ID: 31157891
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of alcohol consumption and smoking on disease damage in systemic lupus erythematosus: data from the Korean Lupus Network (KORNET) registry.
    Kim SK; Lee SS; Choe JY; Park SH; Lee H
    Lupus; 2017 Dec; 26(14):1540-1549. PubMed ID: 28478697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort.
    Bruce IN; O'Keeffe AG; Farewell V; Hanly JG; Manzi S; Su L; Gladman DD; Bae SC; Sanchez-Guerrero J; Romero-Diaz J; Gordon C; Wallace DJ; Clarke AE; Bernatsky S; Ginzler EM; Isenberg DA; Rahman A; Merrill JT; Alarcón GS; Fessler BJ; Fortin PR; Petri M; Steinsson K; Dooley MA; Khamashta MA; Ramsey-Goldman R; Zoma AA; Sturfelt GK; Nived O; Aranow C; Mackay M; Ramos-Casals M; van Vollenhoven RF; Kalunian KC; Ruiz-Irastorza G; Lim S; Kamen DL; Peschken CA; Inanc M; Urowitz MB
    Ann Rheum Dis; 2015 Sep; 74(9):1706-13. PubMed ID: 24834926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.